Literature DB >> 32368996

Epidemiology of yeast species causing bloodstream infection in Tehran, Iran (2015-2017); superiority of 21-plex PCR over the Vitek 2 system for yeast identification.

Mohammad Kord1, Mohammadreza Salehi2, Sadegh Khodavaisy1, Seyed Jamal Hashemi1, Roshanak Daie Ghazvini1, Sassan Rezaei1, Ayda Maleki1, Ahmad Elmimoghaddam1, Neda Alijani3, Alireza Abdollahi4, Mahsa Doomanlou4, Kazem Ahmadikia1, Niloofar Rashidi1, Weihua Pan5, Teun Boekhout6,7, Amir Arastehfar6,7.   

Abstract

Introduction. Given the limited number of candidaemia studies in Iran, the profile of yeast species causing bloodstream infections (BSIs), especially in adults, remains limited. Although biochemical assays are widely used in developing countries, they produce erroneous results, especially for rare yeast species.Aim. We aimed to assess the profile of yeast species causing BSIs and to compare the accuracy of the Vitek 2 system and 21-plex PCR.Methodology. Yeast blood isolates were retrospectively collected from patients recruited from two tertiary care training hospitals in Tehran from 2015 to 2017. Relevant clinical data were mined. Identification was performed by automated Vitek 2, 21-plex PCR and sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2).Results. In total, 137 yeast isolates were recovered from 107 patients. The overall all-cause 30-day mortality rate was 47.7 %. Fluconazole was the most widely used systemic antifungal. Candida albicans (58/137, 42.3 %), Candida glabrata (30/137, 21.9 %), Candida parapsilosis sensu stricto (23/137, 16.8 %), Candida tropicalis (10/137, 7.3 %) and Pichia kudriavzevii (Candida krusei) (4/137, 2.9 %) constituted almost 90 % of the isolates and 10 % of the species detected were rare yeast species (12/137; 8.7 %). The 21-plex PCR method correctly identified 97.1 % of the isolates, a higher percentage than the Vitek 2 showed (87.6 %).Conclusion. C. albicans was the main cause of yeast-derived fungaemia in this study. Future prospective studies are warranted to closely monitor the epidemiological landscape of yeast species causing BSIs in Iran. The superiority of 21-plex PCR over automated Vitek 2 indicates its potential clinical utility as an alternative identification tool use in developing countries.

Entities:  

Keywords:  21-plex PCR; Vitek 2; bloodstream infections; candidaemia

Mesh:

Substances:

Year:  2020        PMID: 32368996     DOI: 10.1099/jmm.0.001189

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  Comparison of PCR-RFLP with 21-plex PCR and rDNA Sequencing for Identification of Clinical Yeast Isolates.

Authors:  Mohammad Kord; Ahmad Elmimoghaddam; Seyed Jamal Hashemi; Sassan Reziae; Roshanak Daie Ghazvini; Mohammadreza Salehi; Alireza Abdollahi; Ali Ahmadi; Muhammad Ibrahim Getso; Teun Boekhout; Sadegh Khodavaisy
Journal:  Mycopathologia       Date:  2021-01-04       Impact factor: 2.574

Review 2.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

3.  Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in Turkey: Evolution of a Persisting Challenge.

Authors:  Amir Arastehfar; Suleyha Hilmioğlu-Polat; Farnaz Daneshnia; Weihua Pan; Ahmed Hafez; Wenjie Fang; Wanqing Liao; Zümrüt Şahbudak-Bal; Dilek Yeşim Metin; João N de Almeida Júnior; Macit Ilkit; David S Perlin; Cornelia Lass-Flörl
Journal:  Front Cell Infect Microbiol       Date:  2021-04-22       Impact factor: 5.293

4.  Comparative genomic analysis of clinical Candida glabrata isolates identifies multiple polymorphic loci that can improve existing multilocus sequence typing strategy.

Authors:  A Arastehfar; M Marcet-Houben; F Daneshnia; S J Taj-Aldeen; D Batra; S R Lockhart; E Shor; T Gabaldón; D S Perlin
Journal:  Stud Mycol       Date:  2021-11-29       Impact factor: 16.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.